Effects of combining two diabetes medications that lower blood sugar: a summary of previous studies

Declarations. Conflict of interests: AA received honoraria for speaker activities, for serving on advisory boards, or consultancy from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Amarin, Bruno Farmaceutici, Amgen, Novo Nordisk, and Sanofi. GPF received honoraria for speaker activities, for serving on advisory boards, or consultancy from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Guidotti, Novartis, Novo Nordisk, and Sanofi. MN, MD, AF, GE, AM, and JB declare no Conflicts.